Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's edition: Lilly plans tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

More from Scrip

More from Scrip's Five Must-Know Things